On Jan. 25, ImClone Systems (NASDAQ:IMCL) released fourth-quarter earnings for the period ended Dec. 31.
- Net revenues surged by 33.5%, primarily driven by a 47% rise in royalty revenues.
- Royalty revenues recorded an impressive $77.1 million, primarily driven by a 38% growth in the sales of cancer drug ERBITUX. The company manufactured ERBITUX; Bristol-Myers Squibb (NYSE:BMY) distributes and markets the drug.
- In the first half of 2007, the company expects to complete phase 1 studies of investigational drugs IMC-1121B and IMC-A12.
- Players in our Motley Fool CAPS stock rating service do not think too highly of ImClone's prospects; the stock has a lowly one-star rating.
(Figures in millions, except per-share data)
Income Statement Highlights
|
Q4 2006 |
Q4 2005 |
Change | |
|---|---|---|---|
|
Sales |
$132.2 |
$99.0 |
33.5% |
|
Net Profit |
$46.6 |
$0.7 |
6,608.6% |
|
EPS |
$0.53 |
$0.01 |
5,200.0% |
|
Diluted Shares |
92.1 |
85.5 |
7.7% |
Get back to basics with a look at the income statement.
Margin Checkup
|
Q4 2006 |
Q4 2005 |
Change* | |
|---|---|---|---|
|
Gross Margin |
75.8% |
72.0% |
3.8 |
|
Operating Margin |
37.1% |
(4.9%) |
42.0 |
|
Net Margin |
35.2% |
0.7% |
34.5 |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$1,044.2 |
$756.4 |
38.0% |
|
Accounts Rec. |
No Data |
$59.3 |
N/A |
|
Inventory |
$102.2 |
$81.4 |
25.6% |
|
Liabilities |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Accounts Payable |
No Data |
$35.5 |
N/A |
|
Long-Term Debt |
$603.8 |
$602.5 |
0.2% |
Learn the ways of the balance sheet.
Cash Flow Highlights
A statement of cash flows was not provided. Booo!
Find out why Fools always follow the money.
Related Companies:
- MedImmune (NASDAQ:MEDI)
- Medarex (NASDAQ:MEDX)
- OSI Pharmaceuticals (NASDAQ:OSIP)
- Amgen (NASDAQ:AMGN)
- Amylin Pharmaceuticals (NASDAQ:AMLN)
Related Foolishness:
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
